SCHEMBL5354863

SCHEMBL5354863

COc1cc(CN2C(=O)CN=C(c3ccccc3)c3cc(Cl)ccc32)cc(OC)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.71
OPRK1 P41145 2/20 0.62
NR1I2 O75469 1/20 0.62
ADORA3 P0DMS8 1/20 0.62
OPRM1 P35372 1/20 0.62
GABRP O00591 1/20 0.60
GABRD O14764 1/20 0.60
CACNA1F O60840 1/20 0.60
ALB P02768 1/20 0.60
GABRA1 P14867 1/20 0.60
GABRB1 P18505 1/20 0.60
GABRG2 P18507 1/20 0.60
GABRB3 P28472 1/20 0.60
GABRA5 P31644 1/20 0.60
GABRA3 P34903 1/20 0.60
AKR1C3 P42330 1/20 0.60
GABRA2 P47869 1/20 0.60
GABRB2 P47870 1/20 0.60
GABRA4 P48169 1/20 0.60
AKR1C2 P52895 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5361219 0.93 TP53 (0.72) TP53OPRK1NR1I2ADORA3OPRM1
SCHEMBL5359525 0.89 NPSR1 (0.65) TP53GABRA1GABRG2GABRB3GABRA5
SCHEMBL5349082 0.88 TP53 (0.84) TP53OPRK1NR1I2ADORA3OPRM1
SCHEMBL607167 0.88 TP53 (0.64) TP53OPRK1NR1I2ADORA3OPRM1
SCHEMBL14064651 0.84 TP53 (0.65) TP53OPRK1NR1I2ADORA3OPRM1
SCHEMBL11964655 0.83 TP53 (0.59) TP53OPRK1NR1I2ADORA3OPRM1
SCHEMBL607145 0.83 TP53 (0.59) TP53OPRK1NR1I2ADORA3OPRM1
SCHEMBL11855695 0.83 OPRK1 (0.69) TP53OPRK1NR1I2ADORA3OPRM1
SCHEMBL5355886 0.82 OPRK1 (0.73) TP53OPRK1NR1I2ADORA3OPRM1
SCHEMBL8276025 0.81 NPSR1 (0.72) TP53GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238685-B2 Benzo-fused heterocycles as endothelin antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2007-07-03 US disclosed
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits ACTELION PHARMACEUTICALS LTD. 2005-06-09 US disclosed
WO-2003013545-A1 NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS ACTELION PHARMACEUTICALS LTD (CH) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits EDNRA, EDNRB, ECE1 TP53 3952/4885OPRK1 222/4885NR1I2 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.